Phenotypic and genotypic characterization of clinical plasmid-mediated quinolone resistance (PMQR) and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales in two healthcare facilities in Douala, Cameroon Authors: Giresse Wilfried Guemkam, Luria Leslie Founou, Patrice Landry Koudoum, Megane Daina Foueyem, Brice Davy Dimani, Medi Sike Christiane, Michel Noubom, Raspail Carrel Founou Published: 2026 ABSTRACT AbstractBackgroundThe emergence and escalation of antibiotic resistance in community and hospital settings remain a major public health concern worldwide. The co-occurrence of fluoroquinolone resistance in extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), which are responsible for life-threatening infectious diseases, poses a critical threat, leading to increase therapeutic costs, prolonged hospital stays, and higher mortality rates, particularly in low- and middle-income countries (LMICs) like Cameroon. Given the lack of data regarding the co-occurrence of plasmid-mediated quinolone resistance (PMQR) among ESBL-E responsible for infectious diseases in Cameroon, this study aims at determining the prevalence, phenotypic and genotypic characterization of PMQR among ESBL-Enterobacterales isolated from clinical samples in two healthcare facilities in Douala, Cameroon.Material and methodsOut of 1,139 non-repetitive clinical samples collected from patients, a total of 140 Enterobacterales were identified from February to May 2024. Identification was done using API20E. ESBL screening was performed using the double-disk synergy test and Chromogenic ESBL Agar. Antimicrobial susceptibility testing was done using a Kirby Bauer Disc Diffusion method. Conventional and multiplex PCR were done for the detection of PMQR and ESBL genes.ResultsOf the different clinical samples collected, Enterobacterales were most isolated from urine (57.1%), endocervical swabs (12.9%), wounds (12.9%), and blood (9.3%). Out of 140 non-duplicate Enterobacterales, the predominant species were Escherichia coli (60/140; 42.9%) and Klebsiella pneumoniae (50/140; 35.7%). The prevalence of ESBL-producing Enterobacterales (ESBL-E) was 64%. Among all ESBL-E, 81.1% and 94.4% were fluoroquinolone and multi-drug resistant (MDR) respectively. The blaCTX‑M (65.6%), blaTEM (55.6%), and aac(6')-Ib (47.8%) were the most frequent resistance genes detected.ConclusionThis study reveals a high prevalence of PMQR among ESBL-producing Enterobacterales in two healthcare facilities in Douala, Cameroon. It also showed that hospitalized patients were more infected than outpatients, suggesting the need to reinforce infection prevention and control measures (IPC). The high prevalence of resistance genes observed among these strains underlines the excessive antibiotic use, highlighting the urgent need for rigorous surveillance systems and the implementation of antimicrobial stewardship (AMS) in these healthcare facilities. An integrated, proactive, and real-time genomic surveillance of AMR is crucial to curb the dissemination of these bacterial AMR in hospital and community settings.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12866-026-05118-0.Keywords: Enterobacterales, ESBLs, PMQR, Clinical samples, Cameroon Introduction Antimicrobial resistance (AMR) has significantly increased over the years, leading to several clinical and economic repercussions globally [1]. The β-lactam and fluoroquinolone families are currently the most commonly used antibiotics to treat infectious diseases caused by Enterobacterales in healthcare facilities [2]. High resistance levels to cephalosporins and fluoroquinolones have been reported and have become a major concern in China and sub-Saharan Africa (sSA) countries [2]. Numerous studies highlighted the emergence of multidrug-resistant-producing Enterobacterales (MDR-E) which has become a major concern in healthcare facilities worldwide [3–7]. Among these critical MDR pathogens, extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) are particularly concerning, being responsible for life-threatening infectious diseases in both healthcare and community settings [3–7]. These MDR-E responsible for these infections are often linked to high morbidity and mortality rates, as well as prolonged hospital stays, when they are associated with numerous genes conferring resistance to beta-lactam and fluoroquinolone families [3–7]. Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) are critical priority pathogens responsible for life-threatening infectious diseases. Their ability to evade a majority of β-lactam antibiotics through increasing intrinsic and acquired-resistance mechanisms poses a significant challenge in low-and middle-income countries (LMICs), where β-lactam are commonly used to treat infectious diseases [1, 8]. The main resistance mechanism involved in this phenomenon remains the production of ESBL enzymes, which inactivate β-lactam antibiotics by opening their β-lactam ring, conferring resistance to penicillins, first-, second-, and third-generation cephalosporins as well as aztreonam [9, 10]. These enzymes contribute significantly to reduce the efficacy of treatment in hospitals, increasing length of stay, hospitalization, and mortality [11]. To overcome to these ESBL-E, fluoroquinolone is mostly used in healthcare facilities in LMICs. Fluoroquinolones (FQs) such as ciprofloxacin are a broad-spectrum agent, extensively used as a first-choice alternative solution to treat community and hospital-acquired infections caused by ESBL-E [12]. Quinolone resistance is commonly associated with two different mechanisms including mutation and plasmid-mediated quinolone resistance (PMQR) [5, 13]. Mutations occurring in the quinolone resistance-determining regions (QRDRs) of DNA gyrase and topoisomerase IV, while plasmid-mediated quinolone resistance (PMQR) is a mechanism conferring resistance using qnr, oqx and aac(6’) genes [5, 13]. These two mechanisms are commonly observed among species belonging to Enterobacterales family leading to reduced therapeutic options, especially among infants and elderly patients [5, 13]. The main resistance genes associated with the PMQR mechanism that inactivate fluoroquinolone antibiotics are qnrA, qnrB, qnrC, qnrD, and qnrVC along with oqxAB and qepA, which activate quinolone efflux pump systems as well as increasing biocide resistance, thereby reducing fluoroquinolone susceptibility [5]. Additionally, the aac(6’)-Ib-cr gene decreases susceptibility to ciprofloxacin and norfloxacin while boosting gentamicin resistance [5]. The widespread challenge of AMR in sub-Saharan Africa, exacerbated by the misuse and overuse of antibiotics, highlights a critical data gap. Specifically, there is a paucity of data regarding PMQR among ESBL-E isolated from clinical samples in Douala, Cameroon. Therefore, this study aims to determine the prevalence, risk factors, phenotypic and genotypic characterization of PMQR among ESBL-E isolated from community and hospitalized patients in Douala, Cameroon. Materials and methods Study design and sites A prospective cross-sectional study was conducted during four-month period, from February to May 2024, in district and tertiary healthcare facilities, encoded for ethical reasons as NDH and LHD for district and tertiary hospitals respectively. These healthcare facilities are located in Littoral region within the Wouri department in Douala, the economic capital of Cameroon. The district and tertiary hospitals are located in two distinct districts of Douala, with NDH located in the third and LHD in the first district. The study involved 1,139 participants, comprising both male and female, in-patients and out-patients from both two hospitals following the health system in Douala, Cameroon. All in-and-outpatients admitted to these hospitals with a presumptive infection during our study period were enrolled. More specifically, all participants with presumptive infections after medical examination who agree to participate by signed informed consent, accepted to fill out the questionnaire and provide a sample were included in the study. This data collection included demographic details, antibiotic use history, and other relevant information from participants. This study was approved by the Centre Region Ethics Committee for Human Research and the approval of the both hospitals under the numbers of (N°101/AR/MINSANTE/DHL) and (N°/L/MINSANTE/DRSPL/DSN/HDN) respectively. Sample collection procedures All microbiological specimens like body fluids including pleural fluid, synovial fluid, ear swabs, sputum, urine, wounds, cerebrospinal fluid, blood, and tracheal aspirates, were processed according to standard protocols already established in the laboratory. After collection, all samples were transported in a cooler box with icepacks within four hours to laboratory with the aid of appropriate transport containers. During the study, a total of 1,139 non-repetitive clinical samples were processed in the microbiological laboratory of these hospitals. Patient information, including age, sex, sample type, referral hospital, location, and prior antibiotic use and exposure, were recorded. Bacterial isolates and identification Each patient's sample was cultured and incubated under optimal conditions according to the standard protocols already established in the laboratory. The clinical samples were composed of urine (n = 487), endocervical swab (n = 195), blood (n = 153), stools (n = 67), wound swabs (n = 55), cerebro-spinal fluids (CSF) (n = 53), pleural fluids (n = 49), urethral swab (n = 37), ascitic fluid (n = 24), and seminal fluid (n = 18). According to the SOPs for various clinical samples already established in the laboratories, all samples mentioned above except (blood, feces, and urine) were seeded using Eosine Methylen Blue (EMB), and only urine was plated into Cystine Lactose Electrolyte Deficient (CLED) agar during 18 to 24 h at 37 °C. Likewise, fecal samples were inoculated into selenite broth and incubated overnight at 37 °C during 24 h. After incubation, the previous selenite was cultured into Salmonella-Shigella (SS) agar for 18 to 24 h at 37 °C. Blood samples were incubated at 37 °C in the Bact/ALERT system (Biomerieux, France) for at least three days for bacterial growth. When bacterial growth was detected, the corresponding vial was removed from the automated system and the sample was seeded on EMB medium as previously described. All growing colonies were routinely identified using conventional biochemical methods including API 20E gallery tests. Antibiotic susceptibility testing The disk diffusion method was used to assess the susceptibility of all ESBL-Enterobacterales against a panel of fifteen antibiotics including: piperacillin/tazobactam (TPZ: 100/10 µg), amoxicillin/clavulanic acid (AMC: 20/10 µg), cefoxitin (FOX: 30 µg), cefotaxime (CTX: 30 µg), cefepime (FEP: 30 µg), gentamicin (GN: 30 µg), ofloxacin (OFX: 5 µg) ciprofloxacin (CIP: 5 µg), levofloxacin (LEV: 5 µg), imipenem (IMP: 10 µg), aztreonam (ATM: 30 µg), chloramphenicol (CHL: 30 µg), trimethoprim/sulfamethoxazole (SXT: 1,25/23,75µg), nitrofurantoin (NIT: 300µg) and fosfomycin (FF: 200µg) as illustrated in Supplementary table I were tested and interpreted according to the recommendations of the Antibiogram Committee of the French Society of Microbiology (CA-SFM, 2023). All isolates were classified as multidrug-resistant (MDR) if they were resistant to at least three or more antimicrobial classes as previously defined [6]. Detection of ESBL phenotype Extended-spectrum β-lactamase-producing Enterobacterales were screened using a double disc synergy test (DDT) combining amoxicillin + clavulanic acid and 3rd-generation cephalosporin discs (cefotaxime, ceftriaxone and ceftazidime), and confirmed by plating these presumptive ESBL producers on CHROMagar™ ESBL (CHROMagar, Paris, France) medium at 37 °C overnight. Isolates were considered potential ESBL producers if they displayed a positive synergy test and grew on CHROMagar™ ESBL. Gene detections using polymerase chain reaction (PCR) methods All clinical ESBL-E isolates previously confirmed were subjected to conventional and multiplex PCR methods. Bacterial DNA was extracted using a protocol described by Zemtsa et al., [14]. The genomic DNA extracted was amplified using a thermal cycler BIO-RAD T100 (Laboratoires Bio-Rad, Marnes-la-Coquette, France) as described [6, 14]. Each amplification occurred in a 10-µL reaction mixture consisting of 5 µL BenTaq polymerase (Beneficial bio, UK), 0.1 µL of each forward and reverse primer (100 µM) set(s), 1.5 µL of template DNA and 3.3 µL (for singleplex reactions: blaSHV, aac(6′)-Ib-cr, oqxA, oqxB and qepA) or 3.1 µL (for blaTEM, and blaCTX-M) or 2.9 µL (for qnrB, qnrS and qnrA multiplex) of nuclease-free sterile distilled water. Amplification steps included: initial denaturation at 95 °C for 3 min, followed by 32 cycles of denaturation at 95 °C for 30 s, annealing gene-specific temperature for 45 s, elongation at 72 °C for 45 s, and final elongation at 72 °C for 6 min in a thermal cycler (Bio-Rad Laboratories, Lasec, South Africa) (Supplementary Table II). Generated amplicons were resolved by agarose gel electrophoresis on a 1.5% (w/v) together with a 50 bp ladder (Biolabs, New England) and run in an electric field of 90 V for 45 min. The gel was then immersed in Ethidium Bromide (EB) solution for 20 min, then rinsed briefly with water. Finally, it was visualized under UV light in the Chemi-XL G-box (Syngene, Cambridge, UK) (Fig. 1). Visualization of resistance genes on G-box. CP = Positive Control ; CN = Negative Control ; Ech = Sample ; Ladder (1350pb, 916pb, 766pb, 600pb) Quality control To ensure the quality of antibiotics, culture media, and AST, quality control was carried out using the wild-type control strain Escherichia coli ATCC 25922. In addition, both negative (deionized sterile water served) and positive control strains, including Escherichia coli ATCC 35218 (For blaTEM), K. pneumoniae ATCC 700603 (For blaSHV), and previously sequenced strains harboring all β-lactamase and quinolone resistance genes at the Global Health Research Unit in Nigeria (GHRU), found (unpublished data), were also used. Statistical analysis The data collected was encoded and analyzed on an Excel spreadsheet (Microsoft Excel 2016) and SPSS version 27, applying the Chi2 test. A p-value of less than 5% was considered statistically significant. Results Socio-demographic characteristics and risk factors associated with Enterobacterales A total of 1,139 clinical samples were collected, 634 (55.7%) were taken from women and 505 (44.3%) from men. A total of 390 (34.2%) clinical samples were positive with 140 (35.9%) being Enterobacterales and 250 non-Enterobacterales identified in both hospitals. Among the 390 positive samples, 269 (69%) and 121 (31%) were identified among female and male respectively. A total of (55%; 77/140) and (45%; 63/140) Enterobacterales were recorded among female and male, and the sex ratio (F/M) was 1.4. The age group most affected at the LHD was between 46—55 years (23.2%; 22/95). However, children under five (35.6%; 16/45) were predominantly infected at NDH. The principal clinical samples collected were urine (n = 487, 42.8%) and endocervical swabs (n = 195, 17.1%), with most positive Enterobacterales being collected from urine (57.1%), followed by female endocervical swabs (12.9%), wound (12.9%), and blood (9.3%) (Table 1). Table 1Socio-demographic characteristics and risk factorsVariablesClinical samples n(%) N = 1139p-valueEnterobacterales identified n(%) n = 140p-valueGenderFemale634 (55,7)0,25581 (57,9)0,004Male505 (44,3)59 (42,1)Age ranges[0—5]196 (17,2)0,05427 (19,3) 0,001[6—15]50 (4,4)0 (0,0)[16—25]135 (11,8)13 (9,3)[26—35]200 (17,6)21 (15,0)[36—45]185 (16,2)17 (12,1)[46—55]144 (12,6)24 (17,2)[56—65]93 (8,2)9 (6,4)[66—75]94 (8,3)18 (12,9)[76—85]33 (2,9)9 (6,4)[86—95]7 (0,6)1 (0,7)[96—105]2 (0,2)1 (0,7)Collection sitesNDH182 (16,0) < 0,00145 (32,1) < 0,001LHD957 (84,0)95 (67,9)Patient typesOut-patients588 (51,6)0,96368 (48,6)0,107In-patients551 (48,4)72 (51,4)WardsSurgery133 (2,9)0,33710 (7,1) < 0,001Outpatient consultation70 (6,1)9 (6,4)External588 (51,6)68 (48,6)Gynecology28 (2,5)5 (3,6)Internal medicine99 (8,7)13 (9,3)Neonatology54 (4,7)6 (4,3)Pediatrics60 (5,3)10 (7,1)Resuscitation28 (2,5)2 (1,4)Emergencies68 (6,0)8 (5,8)VIP36 (3,1)2 (1,4)Others275 (6,6)7 (5,0)SpecimensStool67 (5,9) < 0,0014 (2,9) < 0,001Urine487 (42,8)80 (57,1)Blood153 (13,4)13 (9,3)CSF53 (4,7)0 (0,0)Pleural fluid49 (4,3)3 (2,1)Others puncture fluids325 (2,2)2 (1,4)Endocervical swabs195 (17,1)18 (12,9)Urethral swabs455 (4,8)2 (1,4)Wounds55 (4,8)18 (12,9)Total1,139 (100,0)140 (100,0)1 = Surgery and operating room; 2 = Sickle cell disease, Infection, Oncology; 3 = Joint fluid, ascites fluid; 4 = Urethral sampling and sperm culture Socio-demographic characteristics and risk factors 1 = Surgery and operating room; 2 = Sickle cell disease, Infection, Oncology; 3 = Joint fluid, ascites fluid; 4 = Urethral sampling and sperm culture Distribution of Enterobacterales among clinical samples A total of 140 Enterobacterales were identified in tertiary (67.85%; 95/140) and district (32.15%; 45/140) hospitals. E. coli (42.9%; 60/140) and K. pneumoniae (35.7%; 50/140) were the leading species identified in both two hospitals. The prevalence of E. coli and K. pneumoniae among tertiary hospitals were (40%; 38/95) and (35.8%; 34/95) respectively (Fig. 2; Supplementary table III). At the district hospital level, the prevalence of E. coli and K. pneumoniae were (48.9%; 22/45) and (35.6%; 16/45) respectively. Other species that were identified in tertiary and district hospitals included Proteus spp [(7.4%; 7/95) vs (4.4%; 2/45)], Enterobacter spp [(6.3%; 6/95) vs (4.4%; 2/45)], K. oxytoca, K. rhinoscleromatis, and K. ornithinolytica, which accounted for 6.4% (9/140) for each, respectively (Table 2). Prevalence of ESBL-E strains in hospital settings. Table 2Distribution of PMQR-ESBL-E and MDR-ESBL-E according to the speciesEnterobacterales strainsESBL (n)PMQR-ESBL(n)MDR-ESBL(n)NoYesNoYesCitrobacter freundii10101Enterobacter aerogenes21102Enterobacter agglomerans20202Enterobacter cloacae31212Enterobacter sakazakii11001Escherichia coli39633138Klebsiella ornithinolytica20202Klebsiella oxytoca31203Klebsiella pneumoniae33627330Klebsiella rhinoscleromatis21102Proteus mirabilis10101Proteus rettgeri10101Total901773585 Distribution of PMQR-ESBL-E and MDR-ESBL-E according to the species Prevalence of ciprofloxacin-resistance among ESBL-producing Enterobacterales Out of 1,139 clinical samples, 140 Enterobacterales were identified and 90 (64.3%) were ESBL producers. Among this Enterobacterales identified, highest rates of ESBL and ESBL-PMQR phenotypes were recorded in LHD compared to NDH hospitals (Fig. 3). Among these ESBL-Enterobacterales, 81.1% (73/90) were ciprofloxacin resistance and more than 60% (48/73) were originating from LHD (tertiary hospital) (Fig. 3). Escherichia coli (38/60) and Klebsiella pneumoniae (34/50) were most frequently detected at the LHD out of the 634 samples collected, rather than at the NDH. A total of 61.05% (58/95) of ESBL-E was recorded in the tertiary hospital, compared with 71.11% (32/45) in the 2nd category hospital. The main ESBL-E species were ESBL-E. coli 43.4% (39/90) and ESBL-K. pneumoniae 36.8% (33/90) isolated from all clinical samples (Table 2). The frequencies of ciprofloxacin resistance were higher in ESBL-E. coli 45.2% (33/73) compared to ESBL-K. pneumoniae 31.5%(23/73) Fig. 4. Distribution of resistance phenotypes per hospital. LDH: Tertiary Hospital; NDH: District Hospital Distribution of Enterobacterales according to the healthcare facilities. LDH: Tertiary Hospital; NDH: District Hospital Antibiotic susceptibility testing (AST) of ESBL-E Antimicrobial resistance profile of ESBL-PE is presented in Fig. 5. High resistance level was observed for amoxicillin/clavulanic acid (100%), aztreonam (97%), cefotaxime (96%), cefepime (93%), ofloxacin (89%), trimethoprim/sulfamethoxazole (82%), ciprofloxacin (81%), and levofloxacin (79%). This high resistance was particularly observed among ESBL-E. coli and ESBL-K. pneumoniae with amoxicillin/clavulanic acid (100% for both), and to the 3rd generation cephalosporins such as cefotaxime and the monobactams such as aztreonam. Low resistance level of ESBL-Enterobacterales was observed for fosfomycin (19%) and imipenem (16%). High frequency of ESBL-MDR (63.5%; 54/85) and ESBL-PMQR (65.8%; 48/73) were observed at the tertiary hospital compared to the district hospital (Supplementary table IV). Finally, internal medicine was the most affected wards in both two hospitals with the highest resistance level against all antibiotics tested (Fig. 6). Resistance profile of ESBL-producing Enterobacterales. AMC = amoxicillin/clavulanic acid; ATM = aztreonam; CTX = cefotaxime; FEP = cefepime; OFX = ofloxacin; SXT = trimethoprim/sulfamethoxazole; CIP = ciprofloxacin; LEV = levofloxacin; PTZ = piperacillin/tazobactam; FOX = cefoxitin; NI = nitrofurantoin; GEN = gentamicin; CHL = chloramphenicol; FOS = Fosfomycin; IMP = imipenem Resistance profiles according to the wards. PTZ = piperacillin/tazobactam; AMC = amoxicillin/clavulanic acid; IMP = imipenem; FOX = cefoxitin; CTX = cefotaxime; FEP = cefepime; ATM = aztreonam; OFX = ofloxacin; CIP = ciprofloxacin; LEV = levofloxacin; FOS = Fosfomycin; GEN = gentamicin; NI = nitrofurantoin; SXT = trimethoprim/sulfamethoxazole; CHL = chloramphenicol; Surgery and specialities = Surgery and operating room; Others = Sickle cell disease, Infection, Oncology, VIP: High-standing room Multidrug resistance and resistance patterns of MDR-E Overall, 94.4% (85/90) of ESBL-E were multidrug resistant, with children under five (21.2%; 18/85) and elderly [66—75] years (17.6%, 15/85) being most infected by these MDR isolates. This MDR resistance was particularly observed in the external consultation ward (48.2%; 41/85). The urine samples were more positive to MDR-E (56.7%; 59/104) than endocervical swabs (13.5%; 14/104), and wound samples (13.5%; 14/104). Among all MDR-Enterobacterales the most common species were MDR-E. coli and MDR-K. pneumoniae (Table 2). The most common resistance patterns among all MDR-ESBL-Enterobacterales were PTZ-AMC-FOX-CTX-FEP-ATM-OFX-CIP-LEV-FUR-SXT and PTZ-AMC-FOX-CTX-FEP-ATM-OFX-CIP-LEV-SXT (Supplementary Fig. 1), which appeared among five species, including 4 Escherichia coli and 1 Klebsiella pneumoniae, followed by -AMC-CTX-FEP-ATM-OFX-CIP-LEV-SXT observed in four isolates of Escherichia coli. Characterization of PMQR and ESBL encoding genes Out of 90 ESBL, 73 (81.1%) were PMQR-ESBL-producing Enterobacterales with the frequencies of PMQR-ESBL-E. coli and PMQR-ESBL-K. pneumoniae being (45.2%; 33/73) and (36.98%; 27/73) (Table 2). The Fig. 7 shows the distribution of PMQR and ESBL resistance genes among ESBL-Enterobacterales according to the healthcare facilities and highlighted the highest rates of all genes in LHD compare to NDH hospitals. Molecular analysis reveals that the most prevalent resistance genes across both hospitals were blaCTX-M (65.6%; 59/90), blaTEM (55.6%; 50/90), aac(6')-Ib (47.8%; 43/90), oqxB and qnrB (33.3%; 30/90), oqxA (32.2%; 29/90), blaSHV (27.8%; 25/90), qnrS (14.4%; 13/90), and qnrA (6.7%; 6/90) (Fig. 7 and supplementary table VI). The qepA (1.1%; 1/90) was only detected at the LHD. In LHD hospital, the co-resistance of PMQR and β-lactam genes were observed with a high rates among species including aac(6')-Ib/blaTEM (54%; 27/50); oqxB/blaTEM (46%; 23/50); aac(6')-Ib/blaCTX-M (61%; 36/59); oqxA/blaCTX-M (44%; 26/59); aac(6')-Ib/blaSHV and oqxA/blaSHV (60%; 15/25); qnrB/blaSHV (44%; 11/25) (Fig. 7) (Table 3). Distribution of resistance genes according to the hospitals. NDH: District Hospital; LDH: Tertiary Hospital Table 3Distribution of ESBL-E according to the species, resistance profile, resistance genes and hospitalsCollection sitesLHD (n = 58)NDH (n = 32)LHD (n = 58)NDH (n = 32)LHD (n = 58)NDH (n = 32)ESBL-EnterobacteralesCitrobacter freundii10Resistance profilePTZ3721GenesblaTEM2822Enterobacter aerogenes11AMC5832Enterobacter agglomerans11IMP86blaCTX-M3722Enterobacter cloacae30FOX3721Enterobacter sakazakii10CTX5630blaSHV1510Escherichia coli2514FEP5232ATM5730qnrA33Klebsiella ornithinolytica20OFX5129qnrB1812Klebsiella oxytoca21CIP4825LEV4922qnrS112Klebsiella pneumoniae2211FOS98aac(6')-Ib2617GEN1516Klebsiella rhinoscleromatis02NI2417qepA10Proteus mirabilis01SXT4727oqxA209Proteus rettgeri01CHL198oqxB237LHD Tertiary Hospital, NDH District Hospital, E Sample, PTZ piperacillin/tazobactam, AMC amoxicillin/clavulanic acid, IMP imipenem, FOX cefoxitin, CTX cefotaxime, FEP cefepime, ATM aztreonam, OFX ofloxacin, CIP ciprofloxacin, LEV levofloxacin, FOS Fosfomycin, GN gentamicin, NIT nitrofurantoin, SXT trimethoprim/sulfamethoxazole, CHL chloramphenicol Distribution of ESBL-E according to the species, resistance profile, resistance genes and hospitals LHD Tertiary Hospital, NDH District Hospital, E Sample, PTZ piperacillin/tazobactam, AMC amoxicillin/clavulanic acid, IMP imipenem, FOX cefoxitin, CTX cefotaxime, FEP cefepime, ATM aztreonam, OFX ofloxacin, CIP ciprofloxacin, LEV levofloxacin, FOS Fosfomycin, GN gentamicin, NIT nitrofurantoin, SXT trimethoprim/sulfamethoxazole, CHL chloramphenicol Discussion Enterobacterales cause a wide range of infections, commonly colonize and spread in the human body. In recent years, the increasing prevalence of ESBL-producing-Enterobacterales observed in healthcare facilities poses a significant public health threat in sub-Saharan Africa (sSA). The situation is exacerbated by inadequate infection prevention and control measures (IPC) coupled with ineffective management of antibiotic use in healthcare facilities [7]. Their significant contribution to increasing morbidity and mortality rates has already been established [6]. The increasing antibiotic resistance within this bacterial family is due to the overproduction of β-lactamase enzymes, which limits effective treatment options [5, 7]. The widespread use of fluoroquinolones in healthcare facilities has inadvertently facilitated the emergence and escalation of antimicrobial resistance, complicating the management of infectious diseases [5]. The aim of this study was to determine the prevalence, phenotypic and genotypic characterization of PMQR among ESBL-Enterobacterales isolated from various clinical samples in two healthcare facilities following the health system in Douala, Cameroon. Out of all various clinical samples, the most representative samples were urine and endocervical swabs. These samples were mainly from females, representing 57.9% of Enterobacterales identified. The sex ratio (F/M) observed was 1.4, which is in agreement with the results obtained by Nkengkana et al., in 2023 in the West region of Cameroon, where he had investigated ESBL-Enterobacterales in the clinical samples in two biggest regional hospitals [6]. Among the urine samples collected and analyzed, 57.1% (80/140) of Enterobacterales were identified, while most of them, 56.3% (45/80), were from females. This higher prevalence in women could be attributed to their urinary tract anatomy, close to the anal orifice, which favors easier colonization and subsequent infection [15]. The prevalence of ESBL producers was 64.3%. This result is close to those obtained in Benin in 2016, where a 56.2% prevalence of ESBL-Enterobacterales was reported [16]. Other studies in Cameroon have shown similar prevalences, such as Bayaba et al., (2025) from urinary tract infections in West region (64.70%) [3], Mahamat et al., in Yaoundé in 2024 from childhood diarrhea (52.38%) [4]. A systematic review on the genetic determinants of resistance in ESBL-producing Enterobacterales in community and hospital settings in Eastern, Central, and Southern Africa indicated that the prevalence of ESBL-Enterobacterales varies between [62—92%] from country to country within these regions. Intriguingly, the studies conducted in Democratic Republic of Congo, followed by Tanzania and Malawi, highlighted the highest prevalence of ESBL-Enterobacterales among various clinical samples collected from different departments among in-and-outpatients attending tertiary hospitals, with 92%, 89% and 62%, respectively [17–19]. This discrepancy could be attributed to the various epidemiological factors, unavailability of antibiotic policies, and/or lack of infection prevention and control measures implemented depending on the regions. As for fluoroquinolones, the situation is worrying, with a high resistance rate observed for ofloxacin (88.9%), ciprofloxacin (81.1%), and levofloxacin (78.9%). This could be due to the fact that, over the years, fluoroquinolones have been used to treat patients with ESBL-E infections, which could have then led to the emergence of plasmid-mediated fluoroquinolone resistance in the country [20]. It is also important to understand the key species contributing to these alarming resistance rates is crucial. Here we report the predominance of Escherichia coli and Klebsiella pneumoniae among Enterobacterales strains in both settings. This finding are consistent with those obtained in a study conducted from 2005 to 2012 in Douala in Cameroon, which indicated that Escherichia coli (48.5%) and Klebsiella pneumoniae (32.8%) were the most common isolates identified from various clinical samples [21]. In addition, the study carried out by Djuikoue et al., in Cameroon in 2018 revealed comparable prevalences, with Escherichia coli being predominant (50%), followed by Klebsiella pneumoniae (37.5%) [22]. Similarly, studies carried by Nkengkana et al., (2023), investigating Enterobacterales isolated from clinical samples in healthcare facilities have also obtained Escherichia coli and Klebsiella pneumoniae as a principal species in various clinical samples [6]. This may be due to their ability to survive in a variety of environments, and could easily be transmitted from community environment to people who lack hygiene measures and sanitation as already documented [23]. Moreover, the remarkable ability of Klebsiella pneumoniae to form biofilms enables it to adhere to hospital surfaces, medical devices, and tissues, making it the best contributor to hospital-acquired infections [24]. Antimicrobial susceptibility testing reveals the high resistance level among ESBL-Enterobacterales, including ESBL-E. coli and ESBL-K. pneumoniae. Altogether, a relatively high resistance was observed for amoxicillin/clavulanic acid (100%), aztreonam (97%), cefotaxime (96%), cefepime (93%), ofloxacin (89%), trimethoprim/sulfamethoxazole (82%), ciprofloxacin (81%) and levofloxacin (79%) underlining a major crisis in the treatment of such infections in our setting.The high resistance to fluoroquinolones, with rates of 81% for ciprofloxacin and 79% for ofloxacin, also indicates that the treatments usually prescribed for urinary and respiratory infections may be ineffective. The high prevalence of Enterobacterales harboring ESBL and PMQR determinants observed in the study could be attributed to the extensive use of over-the-counter β-lactams and fluoroquinolones in hospital settings, as well as the easy access to antibiotics in the community [25]. The study conducted by Ebongue et al., (2015) at the Douala General Hospital revealed high resistance level to β-lactam (44%) and fluoroquinolone (50%) families among Enterobacterales isolated in this hospital [21]. The authors suggested that counterfeit, improper use, overuse of antibiotics, non-compliance with the treatment duration, and self-medication largely contribute to increase levels of resistance. To escape the activities of β-lactams and fluoroquinolones, ESBL-producing Enterobacterales have developed various mechanisms, including production of ESBL enzymes and/or carrying plasmids that harbor quinolone resistance determinants reducing the susceptibility of ciprofloxacin. The most common genes conferring resistance to β-lactams were blaCTX-M and blaTEM, with the prevalence of 65.6% and 55.6% respectively. This finding is in agreement with the study conducted by Nkengkana et al., (2023) in the West region in Cameroon, where blaCTX-M and blaTEM were the most prevalent β-lactam resistance genes detected in ESBL-Enterobacterales, especially ESBL-E. coli and K. pneumoniae [6]. This is similar to a recent Ghanaian study conducted, which reported 74% and 63% for blaCTX-M and blaTEM, respectively [26]. The predominance of blaCTX-M genes among the community could indicate potential dissemination to other interfaces, including healthcare settings [26]. The most frequent fluoroquinolone and aminoglycoside resistance genes detected were oqxB (33.3%), oqxA (32.2%), qnrB (33.3%), and aac(6')-Ib (47.8%). Among ESBL-E. coli, the most frequently detected fluoroquinolone resistance genes wre qnrB and oqxB, whereas ESBL-K. pneumonia, oqxA and qnrB were the most common. Similar results were obtained by Nourouzi et al., (2020) in Iran, who reported a prevalence of 43% of qnrB in ESBL-K. pneumoniae (7.8%; 7/90), followed by ESBL-E. coli (3.3%; 3/90). These findings were also noted in a study conducted in Ghana, where Klebsiella pneumoniae isolates showed the high frequency of qnrS (17.9%), compared to Escherichia coli (4.4%) [27]. A study carried out in Europe indicates that the qnrS gene is more widely distributed than the qnrA gene among clinical isolates [28], which was corroborated by our results. In our study, the qepA gene conferring resistance to certain disinfectants was detected only in Escherichia coli, with a prevalence of 1.1% (1/90). This result is comparable to the 2.9% prevalence reported by Emilia et al., (2020) at three referral hospitals in Yaoundé, Cameroon [27]. The presence of the qepA gene indicates that the pathogen has developed a resistance mechanism (efflux system) which could limit the effectiveness of conventional treatments and increase cross-transmission from hospital environment to hospitalised patients, morbidity and mortality rate [29, 30, 31, 32]. Its detection underscores the need for continuous monitoring of dissemination of horizontal gene transfer between bacteria in hospital and community environments. Conclusion Our study revealed the high burden of ESBL-E and an alarming ciprofloxacin resistance among ESBL-E in a district and tertiary hospital in Douala, Cameroon. The significantly higher prevalence of Enterobacterales observed in tertiary hospital compared to district hospital underscores the need to strengthen infection prevention and control (IPC) measures and limiting the spread of infections in our healthcare settings. The most frequent species identified among clinical isolates remain E. coli and K. pneumoniae in both two healthcare facilities. The blaCTX-M, blaTEM, aac(6')-Ib, oqxB, and qnrB genes were the most commonly detected in both hospitals. The high prevalence of genes conferring resistance to β-lactam, fluoroquinolone and disinfectant families in Enterobacterales from inpatients and outpatients suggest the need for an active real-time genomic surveillance of these pathogens in hospital and community settings. Therefore, it is essential to reinforce AMS programs and IPC measures to curb the emergence and escalation of antimicrobial resistance. Limitation This study highlighted some limitations, including the undetected mutation occurring in the quinolone-determining regions and variants of genes conferring resistance to ESBLs. In addition, this study was only performed in two healthcare facilities in Douala, following the health system, and the epidemiological data are not representative for this region. We thus need to extend this study in all healthcare facilities in Douala to have the best epidemiological data. Finally, a major limitation was the lack of Whole Genome Sequencing (WGS), which is a powerful technique to identify different gene variants. Supplementary Information Supplementary Material 1. Acknowledgements We thank all staff members of two healthcare structures and all participants who agreed to participate in this study. Abbreviations Multidrug resistance Extended Spectrum β-lactamase Extended Spectrum β-lactamase producing-Enterobacterales Plasmid-mediated Quinolone Resistance Authors’ contributions Conceptualization: GWG, RCF and NM; Methodology: GWG and RCF; Microbiological analyses: GWG and MSC. Investigation and molecular analyses: GWG, PLK, MDF, and BDD; Statistical analyses: GWG; Validation: RCF and MN; Resources: GWG, RCF, LLF, and MSC; Writing original draft: GWG and RCF; Review and editing: GWG, NM, MSC, RCF, and LLF; Visualization: GWG, RCF; Supervision: RCF, LLF, and MN; Project administration: RCF and LLF. All authors have read and agreed to the published version of the manuscript. Funding Raspail Carrel Founou received funding from the Mérieux Institute, Lyon, France, for the CAREFOOD project. CAREFOOD project had supported all the molecular aspects of this study. This work was also supported by the Research Institute of the Centre of Expertise and Biological Diagnostic of Cameroon (CEDBCAM-RI). The funders had no role in the study design, nor the decision to submit the work for publication. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project. Data availability The data are available upon request in accordance with confidentiality and privacy regulations from the corresponding author. Declarations Ethics approval and consent to participate This study was approved by the Regional Human Health Research Ethics Committee for the Littoral Region (N°2024/803/CE/CRERSH-LITTORAL, CRERSH-L) and the Institutional Ethics Committee for Research on Human Health for Douala’s University (N°4128CEI-UDO/03/2024/M, CEI-UDo). We subsequently obtained the necessary authorizations to conduct our research at the CEDBCAM Research Institute (N°2024/03/005/L/CEDBCAM-RI/DG/DRD), and both healthcare facilities, including LHD (N°101/AR/MINSANTE/DHL) and NDH (N°/L/MINSANTE/DRSPL/DSN/HDN), were granted. Sample collection was done from all participants who agreed to participate, signed informed consent, fill out the questionnaire and provide a sample were included in the study. The study was conducted in accordance with the declaration of Helsinki. In addition, the research authorizations of the various healthcare structures have been granted. All methods and protocols used were approved by the CEDBCAM-RI in accordance with the relevant international guidelines and regulations for research laboratory ethics. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data are available upon request in accordance with confidentiality and privacy regulations from the corresponding author.